The FDA warns Covidien on missing documentation and delayed management of its recall of the Duet TRS surgical staples that were implicated in 13 patient injuries and 3 deaths.
Updated June 17, 2012, at 3:30 p.m. with comment from Covidien.
The FDA wants Covidien (NYSE:COV) to defend its management of the recall of its Duet TRS surgical staples, which were pulled off the shelves after they were implicated in 13 patients injuries and 3 deaths.
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...